Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta‐Analysis
暂无分享,去创建一个
[1] Zihua Chen,et al. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy , 2023, Frontiers in Immunology.
[2] Ling-Ling Lee,et al. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. , 2022, JAMA dermatology.
[3] J. Silverberg,et al. Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis , 2022, Archives of Dermatological Research.
[4] W. Shen,et al. Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid. , 2021, JAMA dermatology.
[5] Ling-Ling Lee,et al. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease: A Systematic Review and Meta-analysis. , 2021, JAMA dermatology.
[6] Tzeng-Ji Chen,et al. Association between alopecia areata and retinal diseases: A nationwide population-based cohort study. , 2021, Journal of the American Academy of Dermatology.
[7] Sung-Jen Hung,et al. Radiation-induced bullous pemphigoid in a patient with Kaposi's sarcoma , 2021, Zhōnghuá Pífūkē Yīxué Zázhì.
[8] Chun-Ying Wu,et al. Statins did not reduce the mortality risk in patients with bullous pemphigoid: A population-based cohort study , 2021, Dermatologica Sinica.
[9] Chung-Pin Li,et al. Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study , 2021, Dermatology.
[10] Y. Kanthi,et al. Inflammation, Infection and Venous Thromboembolism. , 2021, Circulation research.
[11] S. Massberg,et al. Interplay between inflammation and thrombosis in cardiovascular pathology , 2021, Nature Reviews Cardiology.
[12] K. Wei,et al. Venous thromboembolism in a case with pemphigus vulgaris after infusion of rituximab plus systemic glucocorticoids and azathioprine: A possible adverse effect of rituximab? , 2021 .
[13] Toshiyuki Yamamoto,et al. Erythrodermic bullous pemphigoid , 2021, Zhōnghuá Pífūkē Yīxué Zázhì.
[14] Chung-Pin Li,et al. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. , 2020, Diabetes research and clinical practice.
[15] M. Preusser,et al. Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. , 2020, Blood.
[16] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[17] M. Cushman,et al. Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis , 2020, Circulation.
[18] J. Silverberg,et al. Association of inflammatory skin diseases with venous thromboembolism in US adults , 2020, Archives of Dermatological Research.
[19] M. Amagai,et al. Autoimmune bullous skin diseases, pemphigus and pemphigoid. , 2020, The Journal of allergy and clinical immunology.
[20] J. Silverberg,et al. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. , 2020, Journal of the American Academy of Dermatology.
[21] C. Lemarié,et al. Cytokine and chemokine regulation of venous thromboembolism , 2020, Journal of thrombosis and haemostasis : JTH.
[22] T. Tvedt,et al. The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials , 2019, Blood.
[23] Jessica M Franklin,et al. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.
[24] K. Kridin,et al. The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study , 2019, Front. Immunol..
[25] K. Kridin,et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.
[26] T. Tung,et al. Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study , 2019, Journal of the American Academy of Dermatology.
[27] P. Jagielski,et al. The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center. , 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[28] P. Wells,et al. Venous Thromboembolism: Advances in Diagnosis and Treatment , 2018, JAMA.
[29] Mei-Ching Lee,et al. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease , 2018, JAMA.
[30] D. Zillikens,et al. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid , 2017, Experimental dermatology.
[31] Soyun Cho,et al. Misclassification of study designs in the dermatology literature , 2017, Journal of the American Academy of Dermatology.
[32] I. Dudkiewicz,et al. Venous thromboembolism in patients with pemphigus: A cohort study , 2017, Journal of the American Academy of Dermatology.
[33] A. Aslam,et al. Bullous pemphigoid and pemphigus vulgaris , 2017, British Medical Journal.
[34] Carlo José Freire Oliveira,et al. Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris , 2017, Mediators of inflammation.
[35] C. Hammers,et al. Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. , 2016, Annual review of pathology.
[36] Soo Young Kim,et al. A newly developed tool for classifying study designs in systematic reviews of interventions and exposures showed substantial reliability and validity. , 2016, Journal of clinical epidemiology.
[37] J. Hansen,et al. COPD and risk of venous thromboembolism and mortality in a general population , 2015, European Respiratory Journal.
[38] J. Ioannidis,et al. Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. , 2015, JAMA internal medicine.
[39] F. Rosendaal,et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid , 2015, Thrombosis and Haemostasis.
[40] J. Reserva,et al. Pemphigus vegetans with coexistent herpes simplex infection and deep venous thrombosis of the lower extremities , 2015, BMJ Case Reports.
[41] E. Berti,et al. Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk , 2015, PloS one.
[42] M. Cugno,et al. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[43] K. Ng,et al. Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan , 2015, Journal of thrombosis and haemostasis : JTH.
[44] D. Zillikens,et al. Pemphigoid diseases , 2013, The Lancet.
[45] Jaw-Town Lin,et al. Long‐term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: A 10‐year nationwide cohort study , 2012, Hepatology.
[46] E. Horváth-Puhó,et al. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population‐based case‐control study , 2012, Journal of thrombosis and haemostasis : JTH.
[47] J. Sundquist,et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.
[48] D. Fanoni,et al. Activation of coagulation in bullous pemphigoid and other eosinophil‐related inflammatory skin diseases , 2011, Clinical and experimental immunology.
[49] Sreeram V Ramagopalan,et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.
[50] S. Goldhaber. Risk factors for venous thromboembolism. , 2010, Journal of the American College of Cardiology.
[51] P. Meroni,et al. Skin autoimmunity and blood coagulation , 2010, Autoimmunity.
[52] R. Hubbard,et al. A population‐based study of acute medical conditions associated with bullous pemphigoid , 2009, The British journal of dermatology.
[53] Peter Cummings,et al. The relative merits of risk ratios and odds ratios. , 2009, Archives of pediatrics & adolescent medicine.
[54] D. Fanoni,et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications , 2009, The British journal of dermatology.
[55] Cecilia Becattini,et al. Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis , 2008, Circulation.
[56] M. Inaoki,et al. Antiphospholipid antibodies in patients with autoimmune blistering disease. , 2007, Journal of the American Academy of Dermatology.
[57] M. Inaoki,et al. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases , 2006, Archives of Dermatological Research.
[58] H. Sharif,et al. Pulmonary embolism in pemphigus vulgaris, the need for judicious immunotherapy. , 2005, JPMA. The Journal of the Pakistan Medical Association.
[59] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[60] M. Symons,et al. Hazard rate ratio and prospective epidemiological studies. , 2002, Journal of clinical epidemiology.
[61] L. Wang,et al. High levels of interleukin‐8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T‐cell activities , 2000, The British journal of dermatology.
[62] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[63] A. Mastroianni,et al. The serum levels of sE‐selectin are increased in patients with bullous pemphigoid or pemphigus vulgaris. Correlation with the number of skin lesions and recovery after corsticosteroid therapy , 1997, The British journal of dermatology.
[64] A. Ogdie,et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study , 2018, European heart journal.
[65] F. Rosendaal,et al. Venous thrombosis , 2015, Nature Reviews Disease Primers.
[66] L. Sagi,et al. Novel antiphospholipid antibodies in autoimmune bullous diseases. , 2014, Human antibodies.
[67] Yu-Huei Huang,et al. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. , 2012, The Journal of investigative dermatology.
[68] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.